Immune response to poxvirus infections in various animals

Critical Reviews in Microbiology

Volumn 28, Issue 3, 2002, Pages 149-185

  Smith, Scott A ^a   Kotwal, Girish J ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CHEMOKINE; COMPLEMENT; CYTOKINE; CYTOKINE RECEPTOR; INTERFERON; PROTEIN; REGULATOR PROTEIN; SERINE PROTEINASE INHIBITOR;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CAT; CATTLE; CATTLE DISEASE; CHICK EMBRYO; CHICKEN; CHORIOALLANTOIS; COWPOX VIRUS; DISEASE MODEL; ECTROMELIA VIRUS; FOOT PAD; FOWLPOX VIRUS; GOAT; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INFLAMMATION; INFLAMMATORY CELL; MOLLUSCIPOXVIRUS; MYXOMA VIRUS; NATURAL KILLER CELL; NONHUMAN; ONCOVIRINAE; POXVIRUS; POXVIRUS INFECTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RABBIT; REVIEW; SEQUENCE HOMOLOGY; SHEEP; SMALLPOX VIRUS; SWINE; VACCINIA VIRUS; VIRUS CELL INTERACTION; VIRUS IMMUNITY; VIRUS INFECTION;

ANIMALIA; BOS TAURUS; CAPRA HIRCUS; COWPOX VIRUS; DNA VIRUSES; ECTROMELIA VIRUS; FELIS CATUS; FOWLPOX VIRUS; GALLUS GALLUS; HERPESVIRIDAE; MOLLUSCIPOXVIRUS; MYXOMA VIRUS; ONCOVIRINAE; ORYCTOLAGUS CUNICULUS; OVIS ARIES; POXVIRIDAE; SUS SCROFA; VACCINIA VIRUS; VARIOLA VIRUS; VERTEBRATA;

EID: 0036395201     PISSN: 1040841X     EISSN: None     Source Type: Journal    
DOI: 10.1080/1040-840291046722     Document Type: Review

References (163)

1. Kotwal G.J., Microorganisms and their interaction with the immune system, J. Leukoc. Biol., 62, 415-29, 1997.
2. Howard J., Justus D.E., Totmenin A.V. et al., Molecular mimicry of the inflammation modulatory proteins (IMPs) of poxviruses: evasion of the inflammatory response to preserve viral habitat, J. Leukoc. Biol., 64, 68-71, 1998.
3. Moss B., Poxviridae: The Viruses and Their Replication, in Fundamental Virology, Fields B.N., Knipe D.M., Howley P.M., Eds., Lippincott-Raven, Philadelphia, 1996, 1163-97.
4. Smith S.A. and Kotwal G.J., Virokines: novel immunomodulatory agents, Exp. Opin. Biol. Ther., 1, 343-57, 2001.
5. Buller R.M. and Palumbo G.J., Poxvirus pathogenesis, Microbiol. Rev., 55, 80-122, 1991.
6. Fenner F., Mousepox (infectious ectromelia): past, present, and future, Lab Anim Sci., 31, 553-9, 1981.
7. Bhatt P.N. and Jacoby R.O., Effect of vaccination on the clinical response, pathogenesis and transmission of mousepox, Lab Anim. Sci., 37, 610-4, 1987.
8. Kerr P.J. and Best S.M., Myxoma virus in rabbits, Rev. Sci. Tech., 17, 256-68, 1998.
9. Strayer D.S., Skaletsky E., and Sell S., Strain differences in Shope fibroma virus, An immunopathologic study, Am. J. Pathol., 116, 342-58, 1984.
10. Kurata T., Aoyama Y., and Kitamura T., Demonstration of vaccinia virus antigen in brains of postvaccinal encephalitis cases, Jpn. J. Med. Sci. Biol., 30, 137-47, 1977.
11. Goldstein J.A., Neff J.M., Lane J.M. et al., Smallpox vaccination reactions, prophylaxis, and therapy of complications, Pediatrics, 55, 342-7, 1975.
12. Antoine G., Scheiflinger F., Dorner F. et al., The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses, Virology, 244, 365-96, 1998.
13. Haig D.M. and Mercer A.A., Ovine diseases Orf, Vet. Res., 29, 311-26, 1998.
14. Yirrell D.L., Reid H.W., Norval M. et al., Immune response of lambs to experimental infection with Orf virus, Vet. Immunol. Immunopathol., 22, 321-32, 1989.
15. Lloyd J.B., Gill H.S., Haig D.M. et al., In vivo T-cell subset depletion suggests that CD4+ T-cells and a humoral immune response are important for the elimination of orf virus from the skin of sheep, Vet. Immunol. Immunopathol., 74, 249-62, 2000.
16. Konya J. and Thompson C.H., Molluscum contagiosum virus: antibody responses in persons with clinical lesions and seroepidemiology in a representative Australian population, J. Infect. Dis., 179, 701-4, 1999.
17. Birthistle K. and Carrington D., Molluscum contagiosum virus, J. Infect., 34, 21-8, 1997.
18. Heng M.C., Steuer M.E., Levy A. et al., Lack of host cellular immune response in eruptive molluscum contagiosum, Am. J. Dermatopathol., 11, 248-54, 1989.
19. Charteris D.G., Bonshek R.E., and Tullo A.B., Ophthalmic molluscum contagiosum: clinical and immunopathological features, Br. J. Ophthalmol., 79, 476-81, 1995.
20. Bugert J.J., Melquiot N., and Kehm R., Molluscum contagiosum virus expresses late genes in primary human fibroblasts but does not produce infectious progeny, Virus Genes, 22, 27-33, 2001.
21. Marennikova S.S., Maltseva N.N., Korneeva V.I. et al., Outbreak of pox disease among carnivora (felidae) and edentata, J. Infect. Dis., 135, 358-66, 1977.
22. Crouch A.C., Baxby D., McCracken C.M. et al., Serological evidence for the reservoir hosts of cowpox virus in British wildlife, Epidemiol. Infect., 115, 185-91, 1995.
23. Zhukova O.A., Tsanava S.A., and Marennikova S.S., Experimental infection of domestic cats by cowpox virus, Acta Virol., 36, 329-31, 1992.
24. Hinrichs U., van de P.H., and van den Ingh T.S., Necrotizing pneumonia in a cat caused by an orthopox virus, J. Comp Pathol., 121, 191-6, 1999.
25. Baxby D., Bennett M., and Getty B., Human cowpox 1969-93: a review based on 54 cases, Br. J. Dermatol., 131, 598-607, 1994.
26. Amer M., El Gharib I., Rashed A. et al., Human cowpox infection in Sharkia Governorate, Egypt, Int. J. Dermatol., 40, 14-7, 2001.
27. Yeruham I., Nir O., Braverman Y. et al., Spread of lumpy skin disease in Israeli dairy herds, Vet. Rec., 137, 91-3, 1995.
28. Carn V.M. and Kitching R.P., The clinical response of cattle experimentally infected with lumpy skin disease (Neethling) virus, Arch. Virol., 140, 503-13, 1995.
29. Carn V.M. and Kitching R.P., An investigation of possible routes of transmission of lumpy skin disease virus (Neethling), Epidemiol. Infect., 114, 219-26, 1995.
30. Ngichabe C.K., Wamwayi H.M., Barrett T. et al., Trial of a capripoxvirus-rinderpest recombinant vaccine in African cattle, Epidemiol. Infect., 118, 63-70, 1997.
31. Chihota C.M., Rennie L.F., Kitching R.P. et al., Mechanical transmission of lumpy skin disease virus by Aedes aegypti (Diptera: Culicidae), Epidemiol. Infect., 126, 317-21, 2001.
32. Massung R.F., Jayarama V., and Moyer R.W., DNA sequence analysis of conserved and unique regions of swinepox virus: identification of genetic elements supporting phenotypic observations including a novel G protein-coupled receptor homologue, Virology, 197, 511-28, 1993.
33. Miller R.B. and Olson L.D., Experimental induction of cutaneous streptococcal abscesses in swine as a sequela to swinepox, Am. J. Vet. Res., 41, 341-7, 1980.
34. Teppema J.S. and De Boer G.F., Ultrastructural aspects of experimental swinepox with special reference to inclusion bodies, Arch. Virol., 49, 151-63, 1975.
35. Kim U.H., Mukhajonpan V., Nii S. et al., Ultrastructural study of cell cultures infected with swinepox and orf viruses, Biken. J., 20, 57-67, 1977.
36. Tripathy D.N. and Hanson L.E., Immunity to fowlpox, Am. J. Vet. Res., 36, 541-4, 1975. 35.
37. Kent S.J., Zhao A., Best S.J. et al., Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus, J. Virol., 72, 10180-8, 1998.
38. Leist T.P., Eppler M., and Zinkernagel R.M., Enhanced virus replication and inhibition of lymphocytic choriomeningitis virus disease in anti-gamma interferon-treated mice, J. Virol., 63, 2813-9, 1989.
39. Karupiah G., Fredrickson T.N., Holmes K.L. et al., Importance of interferons in recovery from mousepox, J. Virol., 67, 4214-26, 1993.
40. Ramshaw I.A., Ramsay A.J., Karupiah G. et al., Cytokines and immunity to viral infections, Immunol. Rev., 159, 119-35, 1997.
41. Suenaga T., Okuyama T., Yoshida I. et al., Effect of Mycobacterium tuberculosis BCG infection on the resistance of mice to ectromelia virus infection: participation of interferon in enhanced resistance, Infect. Immun., 20, 312-4, 1978.
42. Aksenov O.A. and Smorodintsev A.A., Experiences with improvement of the neutralization reaction with vaccinia virus in chick fibroblast cultures, J. Hyg. Epidemiol. Microbiol. Immunol., 10, 488-98, 1966.
43. Leddy J.P., Simons R.L., and Douglas R.G., Effect of selective complement deficiency on the rate of neutralization of enveloped viruses by human sera, J. Immunol., 118, 28-34, 1977.
44. Hirsch R.L., The complement system: its importance in the host response to viral infection, Microbiol. Rev., 46, 71-85, 1982.
45. Brier A.M. and Wohlenberg C., Rosenthal J et al. Inhibition or enhancement of immunological injury of virus-infected cells, Proc. Natl. Acad. Sci. U.S.A., 68, 3073-7, 1971.
46. Wakamiya N., Okada N., Wang Y.L. et al., Tumor cells treated with vaccinia virus can activate the alternative pathway of mouse complement, Jpn. J. Cancer Res., 80, 765-70, 1989.
47. Ohta H., Yoshikawa Y., Kai C. et al., Effect of complement depletion by cobra venom factor on fowlpox virus infection in chickens and chicken embryos, J. Virol., 57, 670-3, 1986.
48. Miller C.G., Justus D.E., Jayaraman S. et al., Severe and prolonged inflammatory response to localized cowpox virus infection in footpads of C5-deficient mice: investigation of the role of host complement in poxvirus pathogenesis, Cell Immunol., 162, 326-32, 1995.
49. West B.C., Eschete M.L., Cox M.E. et al., Neutrophil uptake of vaccinia virus in vitro, J. Infect. Dis., 156, 597-606, 1987.
50. Jones J.F., Interactions between human neutrophils and vaccinia virus: induction of oxidative metabolism and virus inactivation, Pediatr. Res., 16, 525-9, 1982.
51. Palumbo G.J., Pickup D.J., Fredrickson T.N. et al., Inhibition of an inflammatory response is mediated by a 38-kDa protein of cowpox virus, Virology, 172, 262-73, 1989.
52. Tsuru S., Kitani H., Seno M. et al., Mechanism of protection during the early phase of a generalized viral infection. I. Contribution of phagocytes to protection against ectromelia virus, J. Gen. Virol., 64, 2021-6, 1983.
53. Hansson O., Johansson S.G., and Vahlquist B., Vaccinia Gangrenosa with normal humoral antibodies. A case possibly due to deficient cellular immunity treated with N-methylisatin betathiosemicarbazone (Compound 33T57, Marboran), Acta Paediatr. Scand., 55, 264-72, 1966.
54. McFarland H.F., Pedone C.A., Mingioli E.S. et al., The response of human lymphocyte subpopulations to measles, mumps, and vaccinia viral antigens, J. Immunol., 125, 221-5, 1980.
55. Perrin L.H., Zinkernagel R.M., and Oldstone M.B., Immune response in humans after vaccination with vaccinia virus: generation of a virus-specific cytotoxic activity by human peripheral lymphocytes, J. Exp. Med., 146, 949-69, 1977.
56. Moretta L., Moretta A., Hengartner H. et al., On the pathogenesis of perforin defects and related immunodeficiencies, Immunol. Today, 21, 593-4, 2000.
57. Doherty P.C. and Korngold R., Characteristics of poxvirus-induced meningitis: virus-specific and non-specific cytotoxic effectors in the inflammatory exudates, Scand. J. Immunol., 18, 1-7, 1983.
58. Yang H., Cain C.A., Woan M.C. et al., Evaluation of hamster natural cytotoxic cells and vaccinia-induced cytotoxic cells for Thy-1.2 homologue by using a mouse monoclonal alpha- Thy-1.2 antibody, J. Immunol., 129, 2239-43, 1982.
59. Jacoby R.O., Bhatt P.N., and Brownstein D.G., Evidence that NK cells and interferon are required for genetic resistance to lethal infection with ectromelia virus, Arch. Virol., 108, 49-58, 1989.
60. Karupiah G., Coupar B.E., Andrew M.E. et al., Elevated natural killer cell responses in mice infected with recombinant vaccinia virus encoding murine IL-2, J. Immunol., 144, 290-8, 1990.
61. Blanden R.V. and Gardner I.D., The cell-mediated immune response to ectromelia virus infection. I. Kinetics and characteristics of the primary effector T cell response in vivo, Cell Immunol., 22, 271-82, 1976.
62. Andrew M.E., Coupar B.E., and Boyle D.B., Humoral and cell-mediated immune responses to recombinant vaccinia viruses in mice, Immunol. Cell Biol., 67, 331-7, 1989.
63. Hapel A. and Gardner I., Appearance of cytotoxic T cells in cerebrospinal fluid of mice with ectromelia virus-induced meningitis, Scand. J. Immunol., 3, 311-9, 1974.
64. Gardner I.D. and Blanden R.V., The cell-mediated immune response to ectromelia virus infection. II. Secondary response in vitro and kinetics of memory T Cell production in vivo, Cell Immunol., 22, 283-96, 1976.
65. Kettle S., Alcami A., Khanna A. et al., Vaccinia virus serpin B13R (SPI-2) inhibits interleukin-1beta- converting enzyme and protects virus-infected cells from TNF- and Fas- mediated apoptosis, but does not prevent IL-1beta-induced fever, J. Gen. Virol., 78, 677-85, 1997.
66. Nash P., Barrett J., Cao J.X. et al., Immunomodulation by viruses: the myxoma virus story, Immunol. Rev., 168, 103-20, 1999.
67. Tewari M., Beidler D.R., and Dixit V.M., CrmA-inhibitable cleavage of the 70-kDa protein component of the U1 small nuclear ribonucleoprotein during Fas- and tumor necrosis factor- induced apoptosis, J. Biol. Chem., 270, 18738-41, 1995.
68. Kotwal G.J., Poxviral mimicry of complement and chemokine system components: what's the end game?, Immunol. Today, 21, 242-8, 2000.
69. Sahu A., Isaacs S.N., Soulika A.M. et al., Interaction of vaccinia virus complement control protein with human complement proteins: factor I-mediated degradation of C3b to iC3b1 inactivates the alternative complement pathway, J. Immunol., 160, 5596-604, 1998.
70. Reynolds D.N., Keeling K.L., Molestina R. et al., Heparin binding activity of vaccinia virus complement control protein confers additional properties of uptake by mast cells and attatchment to endothelial cells, in: Advances in animal virology, Jameel S., Lambris, J.D., eds., Oxford and IBH, New York, 2000, 337-42.
71. Smith S.A., Mullin N.P., Parkinson J. et al., Conserved surface-exposed K/R-X-K/R motifs and net positive charge on poxvirus complement control proteins serve as putative heparin binding sites and contribute to inhibition of molecular interactions with human endothelial cells: a novel mechanism for evasion of host defense, J. Virol., 74, 5659-66, 2000.
72. Al-Mohanna, Parhar R., and Kotwal G.J., Vaccinia virus complement control protein is capable of protecting Xenoendothelial cells from antibody binding and killing by human complement and cytotoxic cells, Transplantation, 71, 796-801 2001.
73. Fleming S.B., Haig D.M., Nettleton P. et al., Sequence and functional analysis of a homolog of interleukin-10 encoded by the parapoxvirus orf virus, Virus Genes, 21, 85-95, 2000.
74. Xiang Y. and Moss B., IL-18 binding and inhibition of interferon gamma induction by human poxvirus-encoded proteins, Proc. Natl. Acad. Sci. U.S.A., 96, 11537-42, 1999.
75. Smith V.P., Bryant N.A., and Alcami A., Ectromelia, vaccinia and cowpox viruses encode secreted interleukin-18-binding proteins, J. Gen. Virol., 81, 1223-30, 2000.
76. Upton C., Macen J.L., Schreiber M. et al. Myxoma virus expresses a secreted protein with homology to the tumor necrosis factor receptor gene family that contributes to viral virulence, Virology, 184, 370-82, 1991.
77. Loparev V.N., Parsons J.M., Knight J.C. et al., A third distinct tumor necrosis factor receptor of orthopoxviruses, Proc. Natl. Acad. Sci. U.S.A., 95, 3786-91, 1998.
78. Upton C., Mossman K., and McFadden G., Encoding of a homolog of the IFN-gamma receptor by myxoma virus, Science, 258, 1369-72, 1992.
79. Alcami A. and Smith G.L., A soluble receptor for interleukin-1 beta encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection, Cell, 71, 153-67, 1992.
80. Spriggs M.K., Hruby D.E., Maliszewski C.R. et al., Vaccinia and cowpox viruses encode a novel secreted interleukin-1- binding protein, Cell, 71, 145-52, 1992.
81. Vacheron F., Rudent A., Perin S. et al., Production of interleukin 1 and tumour necrosis factor activities in bronchoalveolar washings following infection of mice by influenza virus, J. Gen. Virol., 71, 477-9, 1990.
82. Deane D., McInnes C.J., Percival A. et al., Orf virus encodes a novel secreted protein inhibitor of granulocyte- macrophage colony-stimulating factor and interleukin-2, J. Virol., 74, 1313-20, 2000.
83. Senkevich T.G., Bugert J.J., Sisler J.R. et al., Genome sequence of a human tumorigenic poxvirus: prediction of specific host response-evasion genes, Science, 273, 813-6, 1996.
84. Graham K.A., Lalani A.S., Macen J.L. et al., The T1/35kDa family of poxvirus-secreted proteins bind chemokines and modulate leukocyte influx into virus-infected tissues, Virology, 229, 12-24, 1997.
85. Lalani A.S., Graham K., Mossman K. et al., The purified myxoma vires gamma interferon receptor homolog M-T7 interacts with the heparin-binding domains of chemokines, J. Virol., 71, 4356-63, 1997.
86. Quan L.T., Caputo A., Bleackley R.C. et al., Granzyme B is inhibited by the cowpox virus serpin cytokine response modifier A, J. Biol. Chem., 270, 10377-9, 1995.
87. Turner P.C., Sancho M.C., Thoennes S.R. et al., Myxoma virus Serp2 is a weak inhibitor of granzyme B and interleukin-1beta-converting enzyme in vitro and unlike CrmA cannot block apoptosis in cowpox virus-infected cells, J. Virol., 73, 6394-404, 1999.
88. Tewari M., Beidler D.R., and Dixit V.M., CrmA-inhibitable cleavage of the 70-kDa protein component of the U1 small nuclear ribonucleoprotein during Fas- and tumor necrosis factor-induced apoptosis, J. Biol. Chem., 270, 18738-41, 1995.
89. Upton C., Macen J.L., Wishart D.S. et al., Myxoma virus and malignant rabbit fibroma virus encode a serpin-like protein important for virus virulence, Virology, 179, 618-31, 1990.
90. Kotwal G.J. and Moss B., Vaccinia virus encodes two proteins that are structurally related to members of the plasma serine protease inhibitor superfamily, J. Virol., 63, 600-6, 1989.
91. Lomas D.A., Evans D.L., Upton C. et al., Inhibition of plasmin, urokinase, tissue plasminogen activator, and C1S by a myxoma virus serine proteinase inhibitor, J. Biol. Chem., 268, 516-21, 1993.
92. Chernos V.I., Antonova T.P., and Senkevich T.G., Recombinants between vaccinia and ectromelia viruses bearing the specific pathogenicity markers of both parents, J. Gen. Virol., 66, 621-6, 1985.
93. Buller R.M., Chakrabarti S., Moss B. et al., Cell proliferative response to vaccinia virus is mediated by VGF, Virology, 164, 182-92, 1988.
94. Fredrickson T.N., Sechler J.M., Palumbo G.J. et al., Acute inflammatory response to cowpox virus infection of the chorioallantoic membrane of the chick embryo, Virology, 187, 693-704, 1992.
95. Ali A.N., Turner P.C., Brooks M.A. et al., The SPI-1 gene of rabbitpox virus determines host range and is required for hemorrhagic pock formation, Virology, 202, 305-14, 1994.
96. Palumbo G.J., Buller R.M., and Glasgow W.C., Multigenic evasion of inflammation by poxviruses, J. Virol., 68, 1737-49, 1994.
97. Palumbo G.J., Pickup D.J., Fredrickson T.N. et al., Inhibition of an inflammatory response is mediated by a 38-kDa protein of cowpox virus, Virology, 172, 262-73, 1989.
98. Zheng Z.M., Specter S., Zhang J.H. et al., Further characterization of the biological and pathogenic properties of erythromelalgia-related poxviruses, J. Gen. Virol., 73, 2011-9, 1992.
99. Ueda Y., Dumbell K.R., Tsuruhara T. et al., Studies on Cotia virus - an unclassified poxvirus, J. Gen. Virol., 40, 263-76, 1978.
100. Zinkernagel R.M., Althage A., and Jensen F.C., Cell-mediated immune response to lymphocytic choriomeningitis and vaccinia virus in rats, J. Immunol., 119, 1242-7, 1977.
101. Kotwal G.J., Miller C.G., and Justus D.E., The inflammation modulatory protein (IMP) of cowpox virus drastically diminishes the tissue damage by down-regulating cellular infiltration resulting from complement activation, Mol. Cell Biochem., 185, 39-46, 1998.
102. Soekawa M., Morita C., Moriguchi R. et al., Neurovirulence of vaccinia viruses for mice, Zentralbl. Bakteriol., 226, 434-42, 1974.
103. Ginsberg A.H. and Johnson K.P., Vaccinia virus meningitis in mice after intracerebral inoculation, Infect. Immun., 13, 1221-7, 1976.
104. Buller R.M., Smith G.L., Cremer K. et al., Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype, Nature, 317, 813-5, 1985.
105. Kotwal G.J., Hugin A.W., and Moss B., Mapping and insertional mutagenesis of a vaccinia virus gene encoding a 13,800-Da secreted protein, Virology, 171, 579-87, 1989.
106. Flexner C., Hugin A., and Moss B., Prevention of vaccinia virus infection in immunodeficient mice by vector-directed IL-2 expression, Nature, 330, 259-62, 1987.
107. Perera L.P., Goldman C.K., and Waldmann T.A., Comparative assessment of virulence of recombinant vaccinia viruses expressing IL-2 and IL-15 in immunodeficient mice, Proc. Natl. Acad. Sci. U.S.A., 98, 5146-51, 2001.
108. Hugin A.W., Flexner C., and Moss B., Clearance of recombinant vaccinia virus expressing IL-2: role of local host immune responses, Cell Immunol., 152, 499-509, 1993.
109. Karupiah G., Blanden R.V., and Ramshaw I.A., Interferon gamma is involved in the recovery of athymic nude mice from recombinant vaccinia virus/interleukin 2 infection, J. Exp. Med., 172, 1495-503, 1990.
110. Mahalingam S., Farber J.M., and Karupiah G., The interferon-inducible chemokines MuMig and Crg-2 exhibit antiviral activity In vivo, J. Virol., 73, 1479-91, 1999.
111. Martinez M.J., Bray M.P., and Huggins J.W., A mouse model of aerosol-transmitted orthopoxviral disease: morphology of experimental aerosol-transmitted orthopoxviral disease in a cowpox virus-BALB/c mouse system, Arch. Pathol. Lab Med., 124, 362-77, 2000.
112. Bray M., Martinez M., Smee D.F. et al., Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge, J. Infect. Dis., 181, 10-9, 2000.
113. Smee D.F., Bailey K.W., Wong M. et al., Intranasal treatment of cowpox virus respiratory infections in mice with cidofovir, Antiviral Res., 47, 171-7, 2000.
114. Smee D.F., Bailey K.W., and Sidwell R.W., Treatment of cowpox virus respiratory infections in mice with ribavirin as a single agent or followed sequentially by cidofovir, Antivir. Chem. Chemother., 11, 303-9, 2000.
115. Turner G.S., Respiratory infection of mice with vaccinia virus, J. Gen. Virol., 1, 399-402, 1967.
116. Taylor G., Stott E.J., and Wertz G. et al., Comparison of the virulence of wild-type thymidine kinase (tk)- deficient and tk+ phenotypes of vaccinia virus recombinants after intranasal inoculation of mice, J. Gen. Virol., 72, 125-30, 1991.
117. Anderson J.B., Smith S.A., Kotwal G.J. et al., Vaccinia virus complement control protein inhibits hyperacute xenorejection in a guinea pig-to-rat heterotopic cervical cardiac xenograft activation, Transpl. Immunol., in press, 2002.
118. Haber E., Can a viral serine proteinase inhibitor prevent postangioplasty restenosis?, Circulation, 94, 2694-5, 1996.
119. Miller L.W., Dai E., Nash P. et al., Inhibition of transplant vasculopathy in a rat aortic allograft model after infusion of anti-inflammatory viral serpin, Circulation, 101, 1598-605, 2000.
120. Lucas A., Liu L., Macen J. et al., Virus-encoded serine proteinase inhibitor SERP-1 inhibits atherosclerotic plaque development after balloon angioplasty, Circulation, 94, 2890-900, 1996.
121. Liu L., Lalani A., Dai E. et al., The viral anti-inflammatory chemokine-binding protein M-T7 reduces intimal hyperplasia after vascular injury, J. Clin. Invest., 105, 1613-21, 2000.
122. DeBruyne L.A., Li K., Bishop D.K. et al., Gene transfer of virally encoded chemokine antagonists vMIP-II and MC148 prolongs cardiac allograft survival and inhibits donor-specific immunity, Gene Ther., 7, 575-82, 2000.
123. Keeling K.L., Hicks R.R., Mahesh J. et al., Local neutrophil influx following lateral fluid-percussion brain injury in rats is associated with accumulation of complement activation fragments of the third component (C3) of the complement system, J. Neuroimmunol., 105, 20-30, 2000.
124. Hicks R.R., Keeling K., Kotwal G.J. et al., Vaccinia virus complement control protein enhances functional recovery following traumatic brain injury, J. Neurotrauma, 19, 705-14, 2002.
125. Reynolds D.N., Zhang J.-P., Shields C.B. et al., Effects of vaccinia virus complement control protein administration following traumatic spinal cord injury, Unpublished, 2001.
126. Maksymowych W.P., Nation N., Nash P. et al., Amelioration of antigen induced arthritis in rabbits treated with a secreted viral serine proteinase inhibitor, J. Rheumatol., 23, 878-82, 1996.
127. Dahi M.V. and Peterson P.K., Dermatologic manifestations of infectious diseases. The Upjohn Company, Kalamazoo, 1988, 13.
128. Messud-Petit F., Gelfi J., Delverdier M. et al., Serp2, an inhibitor of the interleukin-1beta-converting enzyme, is critical in the pathobiology of myxoma virus, J. Virol., 72, 7830-9, 1998.
129. Chernos V.I., Senkevich T.G., Chelyapov N.V. et al., Biologic properties and genome structure of the recombinants between ectromelia and rabbitpox viruses, Acta Virol., 31, 193-202, 1987.
130. Brandt T.A. and Jacobs B.L., Both carboxy- and amino-terminal domains of the vaccinia virus interferon resistance gene, E3L, are required for pathogenesis in a mouse model, J. Virol., 75, 850-6, 2001.
131. Verardi P.H., Jones L.A., Aziz F.H. et al., Vaccinia virus vectors with an inactivated gamma interferon receptor homolog gene (B8R) are attenuated In vivo without a concomitant reduction in immunogenicity, J. Virol., 75, 11-8, 2001.
132. Zhang W.H., Wilcock D., and Smith G.L., Vaccinia virus F12L protein is required for actin tail formation, normal plaque size, and virulence, J. Virol., 74, 11654-62, 2000.
133. Price N., Tscharke D.C., Hollinshead M. et al., Vaccinia virus gene B7R encodes an 18-kDa protein that is resident in the endoplasmic reticulum and affects virus virulence. Virology, 267, 65-79, 2000.
134. Lin C.L., Chung C.S., Heine H.G. et al., Vaccinia virus envelope H3L protein binds to cell surface heparan sulfate and is important for intracellular mature virion morphogenesis and virus infection in vitro and in vivo., J. Virol., 74, 3353-65, 2000.
135. Tscharke D.C. and Smith G.L., A model for vaccinia virus pathogenesis and immunity based on intradermal injection of mouse ear pinnae, J. Gen. Virol., 80, 2751-5, 1999.
136. Wilcock D., Duncan S.A., Traktman P. et al., The vaccinia virus A4OR gene product is a nonstructural, type II membrane glycoprotein that is expressed at the cell surface, J. Gen. Virol., 80, 2137-48, 1999.
137. Ruby J., Bluethmann H., and Peschon J.J., Antiviral activity of tumor necrosis factor (TNF) is mediated via p55 and p75 TNF receptors, J. Exp. Med., 186, 1591-6, 1997.
138. Sedger L., Ramshaw I., Condie A. et al., Vaccinia virus replication is independent of cellular HSP72 expression which is induced during virus infection, Virology, 225, 423-7, 1996.
139. Rolph M.S., Cowden W.B., Medveczky C.J. et al., A recombinant vaccinia virus encoding inducible nitric oxide synthase is attenuated in vivo, J. Virol., 70, 7678-85, 1996.
140. Parkinson J.E., Sanderson C.M., and Smith G.L., The vaccinia virus A38L gene product is a 33-kDa integral membrane glycoprotein, Virology, 214, 177-88, 1995.
141. Martinez-Pomares L., Thompson J.P., and Moyer R.W., Mapping and investigation of the role in pathogenesis of the major unique secreted 35-kDa protein of rabbitpox virus, Virology, 206, 591-600, 1995.
142. Kettle S., Blake N.W., Law K.M. et al., Vaccinia virus serpins B13R (SPI-2) and B22R (SPI-1) encode M(r) 38.5 and 40K, intracellular polypeptides that do not affect virus virulence in a murine intranasal model, Virology, 206, 136-47, 1995.
143. Tufariello J.M., Cho S., and Horwitz M.S., Adenovirus E3 14.7-kilodalton protein, an antagonist of rumor necrosis factor cytolysis, increases the virulence of vaccinia viras in severe combined immunodeficient mice, Proc. Natl. Acad. Sci. U.SA., 91, 10987-91, 1994.
144. Banham A.H. and Smith G.L., Characterization of vaccinia virus gene B12R, J. Gen. Virol., 74, 2807-12, 1993.
145. Thompson J.P., Turner P.C., Ali A.N. et al., The effects of serpin gene mutations on the distinctive pathobiology of cowpox and rabbitpox virus following intranasal inoculation of Balb/c mice, Virology, 197, 328-38, 1993.
146. Engelstad M. and Smith G.L., The vaccinia virus 42-kDa envelope protein is required for the envelopment and egress of extracellular virus and for virus virulence, Virology, 194, 627-37, 1993.
147. Buller R.M., Chakrabarti S., Cooper J.A., et al., Deletion of the vaccinia virus growth factor gene reduces virus virulence, J. Virol., 62, 866-74, 1988.
148. Chernos V.I., Senkevich T.G., Chelyapov N.V. et al., Biologic properties and genome structure of the recombinants between ectromelia and rabbitpox viruses, Acta Virol., 31, 193-202, 1987.
149. Zavagno G., Jaffe B., Esteban M., Role of prostaglandins and non-steroid anti-inflammatory drugs in the pathogenicity of vaccinia virus, J. Gen. Virol., 68, 593-600, 1987.
150. Werner G.T., Jentzsch U., Metzger E. et al., Studies on poxvirus infections in irradiated animals, Arch. Virol., 64, 247-56, 1980.
151. Guerin J.L., Gelfi J., Camus C. et al., Characterization and functional analysis of Serp3: a novel myxoma virus- encoded serpin involved in virulence, J. Gen. Virol., 82, 1407-17, 2001.
152. Robinson A.J., Muller W.J., Braid A.L. et al., The effect of buprenorphine on the course of disease in laboratory rabbits infected with myxoma virus, Lab Anim., 33, 252-7, 1999.
153. Hnatiuk S., Barry M., Zeng W. et al., Role of the C-terminal RDEL motif of the myxoma virus M-T4 protein in terms of apoptosis regulation and viral pathogenesis, Virology, 263, 290-306, 1999.
154. Lalani A.S., Masters J., Graham K. et al., Role of the myxoma virus soluble CC-chemokine inhibitor glycoprotein, M- T1, during myxoma virus pathogenesis, Virology, 256, 233-45, 1999.
155. Jackson R.J., Hall D.F., and Kerr P.J., Myxoma virus encodes an alpha2,3-sialyltransferase that enhances virulence, J. Virol., 73, 2376-84, 1999.
156. Messud-Petit F., Gelfi J., Delverdier M. et al., Serp2, an inhibitor of the interleukin-1 beta-converting enzyme, is critical in the pathobiology of myxoma virus, J. Virol., 72, 7830-9, 1998.
157. Barry M., Hnatiuk S., Mossman K. et al., The myxoma virus M-T4 gene encodes a novel RDEL-containing protein that is retained within the endoplasmic reticulum and is important for the productive infection of lymphocytes, Virology, 239, 360-77, 1997.
158. Mossman K., Lee S.F., Barry M. et al., Disruption of M-T5, a novel myxoma virus gene member of poxvirus host range superfamily, results in dramatic attenuation of myxomatosis in infected European rabbits, J. Virol., 70, 4394-410, 1996.
159. Mossman K., Nation P., Macen J. et al., Myxoma virus M-T7, a secreted homolog of the interferon-gamma receptor, is a critical virulence factor for the development of myxomatosis in European rabbits, Virology, 215, 17-30, 1996.
160. Macen J.L., Upton C., Nation N. et al., SERP1, a serine proteinase inhibitor encoded by myxoma virus, is a secreted glycoprotein that interferes with inflammation, Virology, 195, 348-63, 1993.
161. Opgenorth A., Graham K., Nation N. et al., Deletion analysis of two tandemly arranged virulence genes in myxoma viras, M11L and myxoma growth factor, J. Virol., 66, 4720-31, 1992.
162. Upton C., Macen J.L., Schreiber M. et al., Myxoma virus expresses a secreted protein with homology to the tumor necrosis factor receptor gene family that contributes to viral virulence, Virology, 184, 370-82, 1991.
163. Verma P.C. and Rai A., Effects of cyclophosphamide on pigs infected and vaccinated with swinepox virus, Indian J. Exp. Biol., 27, 467-8, 1989.